Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: A report from the EORP-AF General Pilot Registry

Europace

Volumn 17, Issue 12, 2015, Pages 1777-1786

  Lip, Gregory Y H ^a,b   Laroche, Cécile ^c   Popescu, Mircea Iaochim ^d   Rasmussen, Lars Hvilsted ^b,e   Vitali Serdoz, Laura ^f   Dan, Gheorghe Andrei ^g   Kalarus, Zbigniew ^h   Crijns, Harry J G M ⁱ   Oliveira, Mario Martins ^j   Tavazzi, Luigi ^k   Maggioni, Aldo P ^c   Boriani, Giuseppe ^l  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c European Society of Cardiology   (France)

^d Clinic of Diabetes and Internal Diseases   (Romania)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF TRIESTE   (Italy)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF LISBON   (Portugal)

^k MARIA CECILIA HOSPITAL   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Guidelines; Mortality; Outcome; Stroke; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART DEATH; HEART INFARCTION; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PACEMAKER IMPLANTATION; PAROXYSMAL ATRIAL FIBRILLATION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PERMANENT ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING; STABLE ANGINA PECTORIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; ORAL DRUG ADMINISTRATION; PILOT STUDY; PROTOCOL COMPLIANCE; REGISTER; RISK ASSESSMENT; RISK FACTOR; STANDARDS; STATISTICAL MODEL; STROKE; TREATMENT OUTCOME; UNNECESSARY PROCEDURE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 84942132036     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv269     Document Type: Article

References (24)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14: 1385-413.
2. National-Institute-for-Health-And-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation. 2014. http://guidance.nice.org.uk/CG180 (Clinical guideline 180
3. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 2014; 35: 3365-76.
4. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. 'Real-World' antithrombotic treatment in atrial fibrillation: The EORP-AF Pilot Survey. Am J Med. 2014; 127: 519-29.e1.
5. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Guideline-Adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007; 153: 1006-12.
6. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY. Prognosis and guideline-Adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest. 2011; 140: 911-7.
7. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014; 111: 933-42.
8. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014; 16: 308-19.
9. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-67.
10. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-Analysis of randomised trials. Lancet. 2014; 383: 955-62.
11. Skjoth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost. 2014; 111: 981-8.
12. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011; 8: 602-6.
13. Larsen TB, Potpara T, Dagres N, Pison L, Estner H, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association. Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace. 2014; 16: 698-702.
14. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF Registry. Thromb Haemost. 2014; 111: 833-41.
15. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z, et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2015; 17: 194-206.
16. Lip GY. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ. 2008; 336: 614-5.
17. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014; 16: 1655-73.
18. Potpara TS, Lip GY, Dagres N, Estner HL, Larsen TB, Blomström-Lundqvist C; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace. 2014; 16: 293-8.
19. Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol. 2014; 113: 480-4.
20. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace. 2012; 14: 666-74.
21. Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost. 2014; 111: 381-3.
22. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110: 1087-107.
23. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013; 110: 1189-98.
24. Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, et al. Safety and efficacy of well managed warfarin A report from the Swedish quality register Auricula. Thromb Haemost. 2015; 113: 1370-7.